SCHEMBL911044

SCHEMBL911044

Oc1ccc2ccsc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.44
ESR2 Q92731 9/20 0.44
CYP1A2 P05177 1/20 0.41
CA2 P00918 1/20 0.40
HTT P42858 2/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2A6 P11509 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766115 1.00 ESR1 (0.44) ESR1ESR2CYP1A2CA2HTT
SCHEMBL534539 0.81 CYP2A6 (0.50) ESR1ESR2CYP1A2CA2MRGPRX4
SCHEMBL30656341 0.81 CYP2A6 (0.50) ESR1ESR2CYP1A2CA2MRGPRX4
SCHEMBL1306994 0.76 CYP2A6 (0.36) MRGPRX4CYP2A6SLC6A2SLC6A4SLC6A3
SCHEMBL13742552 0.75 DYRK1A (0.48) CA2MRGPRX4CYP2A6SLC6A2SLC6A4
SCHEMBL164774 0.73 CYP2A6 (0.50) CA2CYP2A6
SCHEMBL3480312 0.73 CYP2A6 (0.42) ESR1ESR2CA2CYP2A6SLC6A2
SCHEMBL405354 0.71 CYP2A6 (0.41) CYP1A2HTTMRGPRX4CYP2A6
SCHEMBL276241 0.71 CYP2A6 (0.41) CA2MRGPRX4CYP2A6SLC6A2SLC6A4
SCHEMBL18725843 0.71 CYP2A6 (0.36) MRGPRX4CYP2A6SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275716-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-04-15 US disclosed
CN-119768396-A Novel substituted benzothiophene-6-carboxylic acid derivatives, process for their preparation and their therapeutic use 赛诺菲 2025-04-04 CN disclosed
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-02-20 US disclosed
CN-119161384-A Estrogen receptor modulating compounds 雷迪厄斯制药公司 2024-12-20 CN disclosed
CN-112105607-B Estrogen receptor modulating compounds 雷迪厄斯制药公司 2024-08-27 CN disclosed
US-20240174629-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY OTCPHARM JSC (RU) 2024-05-30 US disclosed
CN-117551089-A Estrogen receptor proteolytic modulators and related methods of use 阿尔维纳斯运营股份有限公司 2024-02-13 CN disclosed
CN-110612294-B Human cerebulin ligands and bifunctional compounds comprising same 阿尔维纳斯运营股份有限公司 2024-01-16 CN disclosed
EP-4293017-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY Otcpharm JSC (RU) 2023-12-20 EP disclosed
CN-117222630-A 2-acetamido-6-hydroxy-benzothiophene derivatives having antiviral activity OTC制药公司(JSC) 2023-12-12 CN disclosed
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ELI LILLY AND COMPANY 2004-09-09 US disclosed
EP-1397129-A1 HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2004-03-17 EP disclosed
WO-2004009086-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP ELI LILLY AND COMPANY (US) 2004-01-29 WO disclosed
US-20040009965-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003106462-A1 BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE PFIZER INC. (US) 2003-12-24 WO disclosed
WO-2002094262-A1 HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY (US) 2002-11-28 WO disclosed
EP-0129478-B1 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1990-01-17 EP disclosed
EP-0129478-A2 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1984-12-27 EP disclosed
US-4075227-A NONSTEROIDAL ELI LILLY AND COMPANY (US) 1978-02-21 US disclosed
US-3965182-A Preparation of aniline from phenol and ammonia ETHYL CORPORATION (US) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174629-A1 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY ACE2, ACE, EIF2AK2 ESR1 4305/4885ESR2 3044/4885CYP1A2 178/4885
US-12275716-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 ESR1 15/4885ESR2 3/4885CYP1A2 3656/4885
US-20040176435-A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors ADRA2C, ADRB1, TPH1 ESR1 4199/4885ESR2 4121/4885CYP1A2 99/4885
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF SULT1E1, TPMT, SULT1A1 ESR1 951/4885ESR2 1321/4885CYP1A2 47/4885
US-20040009965-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use DPYD, DHFR, TYMP ESR1 3836/4885ESR2 4064/4885CYP1A2 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.